Now available in Ontario, (Pr)SEEBRI* BREEZHALER*, a long-term once-daily maintenance treatment for chronic obstructive pulmonary disease (COPD)

Sep 03, 2013, 08:00 ET from Novartis Pharmaceuticals Canada Inc.

DORVAL, QC, Sept. 3, 2013 /CNW/ - Ontario patients suffering from chronic obstructive pulmonary disease (COPD) now have access to SEEBRI* BREEZHALER* (glycopyrronium bromide) 50 mcg with its listing as a General Benefit on the Ontario Drug Benefit (ODB) Formulary. SEEBRI* BREEZHALER* is available in pharmacies province-wide.

SEEBRI* BREEZHALER* is a long-acting anticholinergic (LAAC) indicated for long-term, once-daily maintenance bronchodilator treatment in patients with COPD, including chronic bronchitis and emphysema. As an inhaled, steroid-free COPD treatment, SEEBRI* BREEZHALER* is not indicated for the relief of acute deterioration of COPD.1

"We are pleased that the Ontario government recognized the therapeutic value of SEEBRI* BREEZHALER*, leading to its inclusion on the list of recommended drugs reimbursed by the Ontario Public Drug Program. Other provinces are also providing access to this new treatment for Canadians with COPD," said Dr. Riad Sherif B., President of Novartis Pharmaceuticals Canada Inc.

About COPD
COPD is a chronic, progressive respiratory condition characterized by gradual airway obstruction, shortness of breath, cough and sputum production. 2009-2010 estimates show that 4% of Canadians are affected. Cigarette smoking is the principal cause, accounting for 80% of COPD deaths.2

About Novartis Pharmaceuticals Canada Inc.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2012, the company invested close to $100 million in research and development in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. For further information, please consult

*SEEBRI and BREEZHALER are registered trademarks.

1 SEEBRI* BREEZHALER* Product Monograph, October 12, 2012.
2 PHAC. Fast facts about Chronic Obstructive Pulmonary Disease (COPD) 2011. Available from: Accessed March 15, 2013.


SOURCE Novartis Pharmaceuticals Canada Inc.